When was ACS dobfar founded?

ACS dobfar was founded in 1973 and raised its 1st funding round 43 years after it was founded.

Where is ACS dobfar located?

ACS dobfar is headquartered in Tribiano, Italy.

How many employees does ACS dobfar have?

As of Aug 31, 2026, the latest employee count at ACS dobfar is 1063.

Is ACS dobfar a funded company?

ACS dobfar is a funded company, having raised a total of $***** in its 1st and only funding round, a Conventional Debt round on Sep 01, 2016.

When was the latest funding round of ACS dobfar?

ACS dobfar's latest funding was a $***** Conventional Debt round on Sep 01, 2016, with participation from 2 investors.

Where does ACS dobfar rank among its competitors?

ACS dobfar ranks 36th amongst 386 active competitors, of which 15 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Almac Group, which secured $417K in Sep, 2022.

Who are the top competitors of ACS dobfar?

ACS dobfar's top competitors include Concord Biotech, Biophore and Almac Group. Among them, Almac Group secured the most recent funding round in September, 2022.

ACS dobfar - 2026 Company Profile, Funding & Competitors

Company Details

ACS dobfar is a fully integrated manufacturer of APIs as well as Finished Dosage Formulations. Products include cephalosporins, penicillins, Carbapenems and other beta-lactam anti-infectives in API category. Finished dosage form categories include dry powder vials, single and multi dose bags, infusion bags, capsules, non-coated tablets, coated tablets, MR tablets and oral suspensions. Services offered in both categories include generic sales to third parties, custom pharma services for innovators and contract manufacturing. It has about 8 API manufacturing and 4 finished dosage form manufacturing facilities.

Key Metrics

Founded Year

1973

Location

Tribiano, Italy

Stage

Funding Raised

Latest Funding Round

Conventional Debt, Sep 01, 2016, $*****

Investors

Natixis & 1 more

Ranked

36^th among 386 active competitors

Employee Count

1,063 as on Aug 31, 2026

Similar Companies

Concord Biotech & 432 more

View ACS dobfar's full profile

ACS dobfar has raised funding over 1 round. Its latest funding round was a Conventional Debt round on Sep 01, 2016 for $*****. 2 investors participated in its latest round. ACS dobfar has 2 institutional investors.

Here is the list of recent funding rounds of ACS dobfar:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 01, 2016	4395596	Conventional Debt	5976550	5359443	6075633	2327085

Access funding benchmarks and valuations. Sign up today!

View details of ACS dobfar's funding rounds and investors

ACS dobfar's employee count trend

ACS dobfar has 1,063 employees as of Aug 26. Here is ACS dobfar's employee count trend over the years:

Uncover ACS dobfar's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ACS dobfar include Concord Biotech, Biophore and Almac Group. Here is the list of Top 10 competitors of ACS dobfar, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Concord Biotech 1984, Ahmedabad (India), Public	CDMO focused on manufacturing API	$11.3M	Quadria Capital, Helix Investments & 18 others	69/100
2nd	Biophore 2007, Hyderabad (India), Seed	Development and manufacturing of niche pharmaceutical products for the generic industry	$2.74M	Ontario & 6 others	62/100
3rd	Almac Group 2001, Craigavon (United Kingdom), Series D	CRAMS company offering preclinical development and CDMO services, also offering companion diagnostic development	$339M	Genomic Health, Gates & 4 others	57/100
4th	Indoco Remedies 1947, Mumbai (India), Public	Provider of APIs manufacturing and formulation services	-	Baring Private Equity Partners	54/100
5th	Jagsonpal 1964, Delhi (India), Public	Traditional company manufacturing bulk drugs and finished formulations	-	Convergent, Aresko	53/100
6th	Wanbury Limited 1990, Mumbai (India), Public	Manufacturer of anti-diabetic drugs	-	-	53/100
7th	Galenicum 2003, Barcelona (Spain), Late Stage	Turnkey solutions for drug development, manufacturing and regulatory approvals	-	Peninsula Capital	52/100
8th	Amino 1958, Frellstedt (Germany), Unfunded	CDMO focused on amino acids and small molecules	-	-	51/100
9th	Aizant 2005, Hyderabad (India), Series A	Company offering contract development services for small molecules	$7.59M	Zephyr Management, Zephyr Peacock & 39 others	50/100
10th	Asymchem 1995, Morrisville (United States), Public	CDMO providing comprehensive pharmaceutical development and manufacturing solutions globally	-	Hillhouse, CoStone Capital & 5 others	50/100
36th	ACS dobfar 1973, Tribiano (Italy), Funding Raised	Manufacturer of APIs as well as Finished Dosage Formulations	-	Natixis, UniCredit	44/100